JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer

Inclusion Criteria:

* Voluntary participation and written informed consent.
* ≥18 years;
* ECOG performance status score of 0 or 1.
* Expected survival of more than 3 months.
* Histologically or cytologically confirmed recurrent or metastatic cervical cancer.
* At least one measurable lesion in the baseline.
* Adequate organ function.
* Provide primary or metastatic tumor samples.
* Capable and willing to comply with the study protocol, treatment plan, laboratory tests, and other related study procedures.

Exclusion Criteria:

* Tumors with histologic components other than squamous-cell carcinoma and adenocarcinoma.
* Other-malignancy diagnosed within 3 years prior to randomization.
* Active central nervous system metastases.
* Baseline imaging showing tumor invasion, compression of, or arising from vital organs.
* Prior treatment with topoisomerase I inhibitors or topoisomerase I inhibitor based antibody-drug conjugates.
* Inadequate washout from prior therapy before randomization.
* Risk factors for ILD.
* Significant cardiovascular or cerebrovascular disease.
* Clinically-significant gastrointestinal abnormalities.
* History of genital-tract fistula.
* Uncontrolled pleural effusion.
* Active or prior autoimmune-disease .
* Uncontrolled infection.
* Toxicity from previous anti-cancer treatments not recovered to CTCAE Grade ≤1.
* History of ≥Grade 3 immune-related adverse events irAEs.
* Previous allogeneic bone-marrow or solid organ transplantation.
* Allergic reactions or hypersensitivity to any component of JSKN033 or the assigned chemotherapy agent.
* Pregnant or lactating female participants, or women planning pregnancy during the study.
* Conditions affecting study drug treatment safety or compliance, including psychiatric disorders, alcohol abuse, or drug abuse.